Modality
Small Molecule
MOA
WRNi
Target
GIP-R
Pathway
Angiogenesis
UC
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
Mar 2018
→ Oct 2027
Phase 2Current
NCT05800526
1,487 pts·UC
2018-03→2027-10·Not yet recruiting
1,487 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-01tomorrowPDUFA· UC
2027-10-091.5y awayPh2 Data· UC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Not yet…
Catalysts
PDUFA
2026-04-01 · tomorrow
UC
Ph2 Data
2027-10-09 · 1.5y away
UC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05800526 | Phase 2 | UC | Not yet recr... | 1487 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R |